My buddy out in the Tri-Cities directed me toward this stock after learning that this company is the only provider of these isotopes in North America after competition out of Canada closed its doors. I can't find a lot of information on medical Isotope producers on the web. Anyone out there have some input?
They are not the only one and they are NOT the first linear accelerator in North America for production of isotopes. Check out www.tracelifesciences.com. They have been selling radioisotopes in the market for over 3 years with production on a linear accelerator much larger than the one they claim to be installing.
I tried to look up your link again tracelifesciences and it did not work. It doesn't look like you can short a .pk stock. Are you playing options with yourself in the basement when the family is asleep?
No one said anything about them being the only one. He put out the question that he understood there were the only one producing Medical Grade Radioactive Isoptopes. Yes we all know about Trace Life Sciences. Big bulky and yesterday's news.
ADMD has just installed the first COMPACT Linear Accelerator in North America. Being smaller sometimes does indeed have its advantages.
Press Release Source: Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation Installs First Compact Linear Accelerator for Isotope Production in North America
Tuesday March 4, 8:00 am ET
KENNEWICK, Wash., March 4, 2008 (PRIME NEWSWIRE) -- Advanced Medical Isotope Corporation (AMIC)(Other OTC:ADMD.PK - News) reports that it took delivery on Monday of the first compact linear accelerator in North America designed specifically for the production of medical isotopes used in Positron Emission Tomography (PET) imaging, as well as many other important diagnostic and therapeutic medical isotopes. This PULSAR (r) Isotope Production system, which sets a new standard for production of PET and other isotopes using proton beams, is a more compact and reliable alternative to cyclotrons, incorporating proven compact accelerator technology integrated with high production yield targets and advanced chemistry process units.
Production will commence within the next several weeks at the Kennewick production facility, with plans for additional production facilities scheduled in the coming months.
"Our goal is to empower physicians, medical researchers, and biotechnology companies by providing them with essential medical isotopes that heretofore have not been feasible or economical, in an effort to detect and cure human disease," stated William J. Stokes, CEO of AMIC. "With this compact linear accelerator, the first of its kind in North America designed specifically for the production of PET isotopes such as Fluorine-18, Nitrogen-13, Carbon-11, and Oxygen-15, our team will also be able to produce other highly desired longer lived isotopes including Actinium-225, Iodine-123 and Indium-111 for diagnostic as well as therapeutic applications."
Advanced Medical Isotope Corporation is engaged in the development of advanced production systems and processes for bringing previously unavailable medical isotopes to the marketplace and advanced systems for local product production. The field of nuclear medicine has routinely utilized radioisotopes in the diagnosis of disease while new processes are being pioneered for the targeted treatment of diseases such as cancer in preference to surgical techniques. Advanced Medical Isotope Corporation products support the accessibility to these less invasive therapeutic processes by advancing systems for lower cost production and improving supply availability of medical isotopes to hospitals and clinical treatment centers. For more information, please visit http://www.isotopia.us
Forward-Looking Statements Except for historical information contained herein, the matters set forth in this press release, such as statements relating to the company's ability to drive technological developments and the acceptance and timing of product introductions, are forward-looking statements that are subject to risks and uncertainties, including but not limited to, timely developments and acceptance of new products, the impact of competitive products and pricing, the timely developments and release of products by suppliers, and other risks.
Contact: Advanced Medical Isotope Corporation James C. Katzaroff (509) 736-4000 Fax: (509) 736-4000
Jan. 31, 2008 - Research - PLoS Med 3(11): e427(Nov 2006) Medical Isotopes Show Promise in Curing HIV/AIDS The HIV epidemic is a major threat to health in the developing and western worlds. A modality that targets and kills HIV-1-infected cells could have a major impact on the treatment of acute exposure and the elimination of persistent reservoirs of infected cells. The aim of this proof-of-principle study was to demonstrate the efficacy of a therapeutic strategy of targeting and eliminating HIV-1-infected cells with radiolabeled antibodies specific to viral proteins in vitro and in vivo. Go to this link for the entire January 31st Press Release and futher info on isotopes: